Financial Statements · From SEC 10-K & 10-Q XBRL Filings
BridgeBio Pharma Inc. Revenue & Financial Statements
BridgeBio Pharma Inc. reported revenue of $502.1M for the fiscal year ended December 31, 2025, up 126.3% year over year, with net income of $(732.9M) and diluted EPS of $-3.78.
- Company
- BridgeBio Pharma Inc. BBIO · NASDAQ
- Latest fiscal year
- FY ended Dec 31, 2025
- Statements
- Income · Balance Sheet · Cash Flow — 5 fiscal years, 8 quarters
Income Statement
Annual, as reported in 10-K filings. Values in USD.
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | 69.7M | 77.6M | 9.3M | 221.9M | 502.1M |
| Cost of revenue | 2.7M | — | 2.4M | 3.9M | 21.0M |
| Gross profit | 67.0M | — | 6.9M | 218.0M | 481.1M |
| Operating income | (576.6M) | (512.2M) | (607.4M) | (593.0M) | (523.4M) |
| Pretax income | 24K | 427K | (87.4M) | (334.4M) | (294.9M) |
| Net income | (562.9M) | (481.4M) | (642.8M) | (535.8M) | (732.9M) |
| Diluted EPS | — | -3.26 | -3.95 | -2.88 | -3.78 |
| EBITDA | (570.8M) | (505.4M) | (600.9M) | (586.9M) | (518.0M) |
Quarterly
| USD | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 211.1M | 2.2M | 2.7M | 5.9M | 116.6M | 110.6M | 120.7M | 154.2M |
| Cost of revenue | 598K | 598K | 598K | 2.1M | 2.6M | 3.7M | 6.6M | 8.1M |
| Gross profit | 210.5M | 1.6M | 2.1M | 3.8M | 114.0M | 106.9M | 114.1M | 146.1M |
| Operating income | 343K | (175.5M) | (191.8M) | (226.0M) | (104.4M) | (134.3M) | (145.2M) | (139.6M) |
| Pretax income | — | — | — | — | — | (181.7M) | (186.5M) | (194.8M) |
| Net income | (35.2M) | (73.5M) | (162.0M) | (265.0M) | (167.4M) | (181.9M) | (182.7M) | (194.6M) |
| Diluted EPS | -0.20 | -0.39 | -0.86 | -1.42 | -0.88 | -0.95 | -0.95 | -0.99 |
| EBITDA | 1.9M | — | (190.2M) | (224.7M) | (103.1M) | — | (143.8M) | (138.1M) |
Balance Sheet
Fiscal year-end snapshots. Values in USD.
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Total assets | 1.0B | 623.0M | 546.4M | 919.3M | 936.0M |
| Current assets | 888.9M | 548.9M | 477.6M | 720.7M | 797.7M |
| Cash & equivalents | 393.8M | 376.7M | 375.9M | 681.1M | 570.1M |
| Total liabilities | 1.9B | 1.9B | 1.9B | 2.4B | 3.0B |
| Current liabilities | 135.1M | 121.4M | 143.8M | 154.4M | 288.0M |
| Long-term debt | 430.8M | 431.0M | 446.4M | 437.3M | — |
| Total debt | 430.8M | 431.0M | 446.4M | 437.3M | — |
| Stockholders’ equity | (870.4M) | (1.3B) | (1.4B) | (1.5B) | (2.1B) |
| Net debt | 37.0M | 54.3M | 70.5M | (243.8M) | — |
Cash Flow Statement
Annual, as reported in 10-K filings. Values in USD.
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Operating cash flow | (497.9M) | (419.5M) | (527.7M) | (520.7M) | (445.9M) |
| Investing cash flow | (200.8M) | 453.1M | 54.0M | 60.8M | (24.5M) |
| Financing cash flow | 736.4M | (13.1M) | 451.5M | 748.5M | 359.3M |
| Capital expenditure | 13.2M | 4.8M | 1.3M | 933K | 1.1M |
| Free cash flow | (511.2M) | (424.3M) | (529.0M) | (521.7M) | (447.0M) |
| Dividends paid | — | — | — | — | — |
| Stock-based compensation | 99.5M | 91.6M | 108.7M | 95.8M | 133.0M |
Figures are parsed from SEC XBRL company facts and may be derived where issuers report year-to-date values (quarterly figures differenced; Q4 computed as FY minus Q3). Fiscal periods follow each company's fiscal calendar, not calendar years. Historical fact, not investment advice — verify with official SEC filings.
Every BBIO filing, connected
Financials beside price, insider trades, and 8-K events — with alerts the moment something new is filed.